Researchers at the University of Pennsylvania reported an in vivo mRNA-LNP platform capable of selectively reprogramming cytotoxic effector T cells (Teff) by targeting the CX3CR1 marker. The approach uses lipid nanoparticles conjugated to fractalkine to preferentially deliver mRNA to Teff in circulation and lymphoid tissue. The study described delivery of mRNAs encoding proteins such as IL-2 or human CD62 L-selectin, aiming for temporary functional reprogramming inside the body. The work positions the platform as an alternative to ex vivo cell engineering by shifting part of the programming burden to in vivo delivery. The results also add to the growing toolkit for precision immunomodulation using targeted nanoparticles, potentially enabling faster iteration for combination strategies where tuning Teff behavior is central to therapeutic outcomes.